… Acenocoumarol and warfarin have different half-lives and it is not … effectiveness and safety
of acenocoumarol, warfarin, dabigatran, rivaroxaban, apixaban and edoxaban in patients …

… this real-world study, we found that the effectiveness and safety profiles of NOAC and
acenocoumarol … However, in high-risk subgroups, our findings on the efficacy and safety of certain …

… 32,476 participants) [49] used acenocoumarol, and in nine of the … dabigatran has a favorable
impact on effectiveness and safety outcomes compared with VKA in non-Asian real-world …

… In conclusion, NOACs were associated with a superior long-term effectiveness and non-inferior
to superior safety compared to VKAs in an unselected real-world population with AF. …

… and bleeding, in patients initiating apixaban or acenocoumarol for the treatment of nonvalvular
… medical records of patients who initiated apixaban or acenocoumarol between 2015 and …

… patients with AF. Moreover, there is a need to assess the comparative effectiveness and safety
of DOACs in real-world … reviewed and meta-analyzed available real-world data so far [7,8,…

… , acenocoumarol and general VKAs were combined into a single VKA node. Given that there
were only a limited number of studies that included phenprocoumon or acenocoumarol and …

… real-world data, … effectiveness studies have been conducted in a real-world setting, but
an overview of the available evidence remains to be developed. The growing need for real-world …

… in patients with complex comorbid conditions such as chronic kidney disease [8,9] and active
cancer [10], clinical trial and real-world … and warfarin or acenocoumarol. Although causal …

… patients [1]. One of the limitations associated with conventional OACs, such as acenocoumarol
… was to evaluate long-term effectiveness and safety of PSM of OACs in real-world settings. …